Japanese antibody drug TRG-035 enters human trials targeting protein that halts tooth formation after childhood
Viral TikToks promising “pills that regrow teeth” flood your feed faster than you can fact-check them. Coconut oil, eggshell powder, mysterious supplements—the internet’s tooth regrowth industrial complex thrives on desperation and half-truths. But buried beneath the wellness influencer noise lies genuine scientific progress that could actually revolutionize dental care: Japan’s first-in-human trial of TRG-035, a biologic drug designed to grow new teeth from scratch.
Japanese researchers target the molecular brake that stops tooth development after childhood.
TRG-035 works nothing like the mythical tooth regrowth pills cluttering Instagram ads. Developed by Kyoto University spin-out Toregem BioPharma, this antibody-based medicine targets USAG-1, a protein that naturally shuts down tooth formation after your adult teeth emerge. Think of USAG-1 as evolution’s way of saying “you’re done growing teeth now.”
The drug removes that molecular parking brake, potentially allowing dormant tooth buds—present in roughly 1% of people with extra teeth—to reactivate and grow functional replacements.
Animal studies in mice and ferrets showed promising results: single injections produced new, functional tissue without safety issues. Dr. Angray Kang from Queen Mary University of London notes that antibody therapies blocking similar pathways already treat osteoporosis safely, providing baseline confidence in the approach.
Current studies focus on safety, not guaranteeing new teeth for participants.
The ongoing Phase I trial at Kyoto University Hospital enrolled 30 adult males aged 30-64, each missing at least one tooth, running from September 2024 through August 2025. The primary goal? Safety monitoring, not tooth regrowth miracles. Researchers explicitly warn that actual new teeth are unlikely in this initial cohort.
If safety data prove acceptable, the team plans pediatric trials for children aged 2-7 born missing six or more teeth—a condition affecting roughly 1 in 1,000 people. These kids often hide their mouths with masks due to appearance concerns, making them ideal candidates for testing whether dormant tooth buds can be “awakened.”
The timeline remains soberly realistic: commercial availability around 2030 for limited cases, assuming the drug survives all trial phases and FDA review.
Whether TRG-035 delivers on its promise, you’re looking at prescription injections administered in clinical settings—not over-the-counter miracles. For now, implants, bridges, and proper oral hygiene remain your best options for dealing with tooth loss.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。